GOSS NASDAQ
Gossamer Bio, Inc.
1W: -39.1%
1M: -48.5%
3M: -90.6%
YTD: -93.0%
1Y: -83.0%
3Y: -82.7%
5Y: -97.7%
$0.21
+0.01 (+4.58%)
Weekly Expected Move ±9.1%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.10
Neutral
3 bullish
2 neutral
4 bearish
Articles (7d)
9
Daily Sentiment (7 Days)
Articles (95)
GOSS 10-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
Robbins LLP Reminds GOSS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Gossamer Bio, Inc.
Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors
Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
12 Health Care Stocks Moving In Monday's Intraday Session
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript
12 Health Care Stocks Moving In Monday's Pre-Market Session
Here are the major earnings before the open Monday
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens Berman
Lost Money on Gossamer Bio, Inc. (GOSS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
GOSS UPCOMING DEADLINE : The Gross Law Firm Alerts Gossamer Bio, Inc. Stockholders of Securities Class Action - Contact the Firm
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Provided Inadequate Disclosures: Levi & Korsinsky
ROSEN, A LONGSTANDING LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
INVESTOR REMINDER: Berger Montague Notifies Gossamer Bio, Inc. (NASDAQ: GOSS) Investors of a Class Action Lawsuit and Deadline
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Pinterest, Inc. (PINS), New Era Energy & Digital, Inc. (NUAI), and Gossamer Bio, Inc. (GOSS) Announced by Holzer & Holzer, LLC
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing to Disclose Trial Risks: Levi & Korsinsky
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $5.43
12 Health Care Stocks Moving In Friday's After-Market Session
Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm
GOSS DEADLINE TODAY: The Gross Law Firm Alerts Gossamer Bio, Inc. Stockholders of Securities Class Action - Contact the Firm
ROSEN, LEADING INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Gossamer Bio (NASDAQ:GOSS) Stock Price Down 5.8% – Time to Sell?
GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Clinical Execution Failures: Levi & Korsinsky
DEADLINE ALERT for PINS, NUAI, GOSS, MEDP: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action– Hagens Berman
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
DEADLINE ALERT for GOSS, NUAI, MEDP, and STLA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
GOSS Shareholder Alert: Gossamer Bio, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Pinterest, Inc. (PINS), New Era Energy & Digital, Inc. (NUAI), and Gossamer Bio, Inc. (GOSS) Announced by Holzer & Holzer, LLC
Shareholders who lost money in Gossamer Bio, Inc (NASDAQ: GOSS) Should Contact Wolf Haldenstein Immediately
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
Holzer & Holzer, LLC Reminds Investors of June 1, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against New Era Energy & Digital, Inc. (NUAI) and Gossamer Bio, Inc. (GOSS)
GOSS Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Gossamer Bio, Inc. Class Action Lawsuit
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (GOSS)
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Gossamer Bio, Inc. (GOSS) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Gossamer Bio, Inc. Securities and Sets a Lead Plaintiff Deadline of June 1, 2026
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of “Hold” from Brokerages
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
Gossamer Bio downgraded by Cantor on unclear regulatory path for seralutinib
This Box Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Q3 EPS Estimates for Gossamer Bio Boosted by HC Wainwright
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio GAAP EPS of -$0.21 misses by $0.02, revenue of $13.8M beats by $6.28M
Small-Cap healthcare stocks ranked by quant ratings after earnings season
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $6.67 Average Target Price from Brokerages
12 Health Care Stocks Moving In Thursday's Intraday Session
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Catalyst Watch: Jobs report, new Apple products, and a spotlight on software
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript
BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%
Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses
Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks
Gossamer Bio's experimental lung condition drug fails in late-stage trial
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
Stock Traders Purchase High Volume of Gossamer Bio Put Options (NASDAQ:GOSS)
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of “Moderate Buy” from Brokerages
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Corient Private Wealth LLC Purchases 302,200 Shares of Gossamer Bio, Inc. $GOSS
Gossamer Bio Target of Unusually High Options Trading (NASDAQ:GOSS)
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio to Participate in Upcoming Investor Conferences